(MNPR) Monopar Therapeutics - Ratings and Ratios

Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Its pipeline includes MNPR-101-Zr, a urokinase plasminogen activator receptor-targeted radiodiagnostic agent in clinical stages, and MNPR-101-RIT, a radiotherapeutic in late preclinical development for advanced cancers. The company is also advancing Camsirubicin, a novel doxorubicin analog in Phase 1b clinical trials for advanced soft tissue sarcoma, and MNPR-202, an analog designed to overcome resistance to doxorubicin and camsirubicin in cancers.

Monopar has established strategic collaborations, including a partnership with NorthStar to develop radio-immuno-therapeutics for severe COVID-19 and a research agreement with the Cancer Science Institute of Singapore to evaluate MNPR-202 and related analogs across various cancer types. Founded in 2014 and headquartered in Wilmette, Illinois, Monopar operates as a subsidiary of Tacticgem LLC. For more information, visit their website at https://www.monopartx.com.

3-Month Forecast: Based on and , MNPR is expected to experience volatility within a range of $30.54 to $39.68. The SMA 20 ($42.74) and SMA 50 ($34.33) suggest potential resistance and support levels, while the ATR (4.57) indicates moderate price movement. With a market cap of $263.02M and a P/B ratio of 55.12, MNPR remains a high-risk, high-reward small-cap biotech stock.